Aspirin Dosing for Cardiac Indications
For acute coronary syndrome, use a loading dose of 162-325 mg orally (chewed if non-enteric coated) immediately, followed by 75-100 mg daily maintenance; for secondary prevention after myocardial infarction, use 75-100 mg daily indefinitely; aspirin is NOT routinely recommended for primary prevention in most patients. 1
Acute Coronary Syndrome (ACS)
Loading Dose
- 162-325 mg orally as soon as possible on presentation 1
- Non-enteric coated aspirin should be chewed when possible to achieve faster onset of antiplatelet action 1
- Administer even if patient is already on aspirin therapy 1
- Alternative routes: rectal or intravenous (where available) if oral administration not possible 1
Maintenance Dose After ACS
- 75-100 mg daily (non-enteric coated) indefinitely 1
- This low-dose regimen is superior to higher maintenance doses (300-325 mg daily), which showed no additional benefit but increased minor and gastrointestinal bleeding 1
Critical caveat: When using ticagrelor as the P2Y12 inhibitor, aspirin doses must be ≤100 mg daily based on post-hoc analysis showing worse outcomes with higher doses 1
Secondary Prevention After Myocardial Infarction
75-100 mg daily indefinitely is the evidence-based recommendation 2, 1. The 2011 AHA/ACC secondary prevention guideline specifies 75-162 mg daily 2, but the most recent 2025 guideline narrows this to 75-100 mg based on updated evidence showing this lower range provides equivalent efficacy with reduced bleeding risk 1.
Post-PCI Considerations
- After primary PCI for STEMI: 81 mg daily is reasonable in preference to higher maintenance doses 3
- The 2014 NSTE-ACS guideline suggests 81-325 mg daily after PCI, with 81 mg daily being reasonable preference 4
- However, the 2025 guideline supersedes this, recommending 75-100 mg daily as the standard 1
Post-CABG
- Start aspirin within 6 hours after surgery 2
- Dosing: 100-325 mg daily for 1 year appears efficacious 2
- The 2006 guideline recommended starting within 48 hours at 100-325 mg daily 5
Primary Prevention in High-Risk Patients
Aspirin is NOT routinely recommended for primary prevention. The 2019 ACC/AHA primary prevention guideline provides clear direction 6:
Class IIb (May Be Considered)
- 75-100 mg daily might be considered for select adults 40-70 years of age who are at higher ASCVD risk but NOT at increased bleeding risk 6
- This is a weak recommendation reflecting uncertainty about net benefit
Class III: Harm (Should NOT Be Used)
- Do NOT use in adults >70 years of age for primary prevention 6
- Do NOT use in adults of any age who are at increased bleeding risk 6
The rationale: Recent primary prevention trials (conducted with contemporary ASCVD therapies like statins and antihypertensives) show less overall benefit than older trials, with bleeding risks often outweighing benefits 6.
Key Clinical Pitfalls to Avoid
Do not continue high-dose aspirin (325 mg) long-term after ACS: The 2025 guideline clearly shows 75-100 mg daily is superior, with 300-325 mg daily associated with increased bleeding without additional benefit 1
Do not exceed 100 mg daily when using ticagrelor: This specific drug interaction requires strict adherence to lower aspirin dosing 1
Do not use enteric-coated formulations for loading doses: Non-enteric coated aspirin (chewed) provides faster antiplatelet action needed in acute settings 1
Do not prescribe aspirin for primary prevention in patients >70 years: This is a Class III: Harm recommendation 6
Do not add aspirin to oral anticoagulation in chronic coronary syndrome: A 2025 trial showed adding aspirin to anticoagulation increased cardiovascular events, death, and major bleeding 7
Special Populations
Aspirin Allergy/Intolerance
- Use clopidogrel 75 mg daily as alternative 2, 4
- Aspirin desensitization is preferred when possible to allow dual antiplatelet therapy 8
Patients on Anticoagulation
- If compelling indication for anticoagulation exists (atrial fibrillation, prosthetic valve, LV thrombus), use low-dose aspirin 75-81 mg daily in addition to warfarin 2
- However, recent evidence suggests this combination may be harmful in chronic coronary syndrome 7